AI Preventive Care AI Designer Interview Questions

A great answer contrasts treating established disease with early risk detection, and highlights AI's ability to find complex patterns in vast data.

Define FHIR as a modern, API-based interoperability standard. Its importance lies in providing a structured, accessible way to get clinical data.

Should include wearables/sensors, patient-reported outcomes, genomic data, social determinants of health data, or claims data.

Must mention ethics approval, protection of human subjects, and ensuring data privacy and study validity.

Should define it as grouping patients by their predicted likelihood of a future outcome (e.g., hospital readmission) to target interventions.

Expect steps: problem definition with clinicians, data cohort selection, feature engineering (labs, vitals, meds), handling missing data, model choice (logistic regression vs. survival analysis), validation, and interpretation.

Should discuss techniques like deletion (listwise, pairwise), imputation (mean, median, MICE, KNN), and the importance of understanding the missingness mechanism (MCAR, MAR, MNAR).

Critical for clinician trust, model debugging, and patient understanding. Techniques: SHAP values, LIME, or rule-based models. Must link explanation to clinical action.

A strong answer highlights confounders (e.g., healthier patients get the drug), selection bias, and the need for causal inference methods (RCTs, instrumental variables) to make a therapeutic claim.

COM-B = Capability, Opportunity, Motivation -> Behavior. The chatbot should address these: provide easy exercises (Capability), suggest local parks (Opportunity), use motivational interviewing (Motivation).

SDOH are non-medical factors (income, education, housing). Ignoring them leads to biased models that blame individuals for systemic issues and can exacerbate health inequities.

No. This is a classic accuracy paradox. A model that always predicts 'no disease' has 99% accuracy. Need to discuss precision, recall, F1-score, and AUC-ROC as better metrics for imbalanced data.

Data leakage is when information from the future or the outcome leaks into the features during training, inflating performance. Example: using a lab test result that is only ordered because the patient already has symptoms of the disease we're trying to predict.

FL trains a model across multiple institutions without sharing raw patient data, solving the problem of data silos due to privacy regulations (HIPAA) while still enabling model development on diverse datasets.

Should cover data types (typing dynamics, voice patterns, gait via accelerometer, social interaction frequency), time-series models (LSTMs), multi-modal fusion, privacy by design, and the critical need for transparent, opt-in consent.

Beyond tuning the model threshold, the answer should involve redesigning the clinical workflow: tiered alerts (high/medium risk), coupling alerts with actionable order sets, and using AI to suggest alternative diagnoses to reduce false positives.

Should reference FDA's Software as a Medical Device (SaMD) framework. Likely Category II (providing clinical decision support). Evidence requires analytical validation (model performance) and clinical validation (improving patient outcomes in a real-world study).

Steps: 1) Measure bias using fairness metrics (equalized odds, demographic parity). 2) Diagnose source (data imbalance, feature selection, proxies). 3) Mitigate via re-weighting, adversarial de-biasing, or using more equitable features. 4) Document and report transparently.

A digital twin is a dynamic computational model of a patient. Challenges: integrating multi-scale data (genomic to lifestyle), model validation, simulation fidelity, and the profound ethical issues of simulating health trajectories and intervention impacts.

Should include a monitored learning loop: rigorous input data monitoring, performance drift detection, scheduled retraining with human-in-the-loop review, A/B testing of new models, and version control with rollback capabilities. Compliance requires audit trails.

KPIs should measure clinical impact and system performance: Patient engagement rate, Time-to-intervention, Reduction in predicted risk score over time, Model fairness metrics, Clinician adoption/override rate, and ultimately, reduction in disease incidence or healthcare costs.

Hospital data: rich clinical context, but episodic, structured, and siloed. Wearable/PRO data: continuous and patient-generated, but noisy, unstructured, and lacks clinical labels. Trade-offs in data quality, labeling cost, model generalizability, and patient engagement.

Must address: 1) Ethical risk of labeling and pathologizing individuals, 2) Potential for coercive intervention, 3) Model bias (it only works on users of that platform), 4) Need for a 'clinician in the loop' for outreach, and 5) Transparent opt-out mechanisms.

Acknowledge their valid concern. Respond by providing a detailed explanation for that specific patient's prediction using SHAP values, showing which factors contributed most. Offer to discuss the model's validation evidence and explore a shared decision-making approach.

Cautious support. Key validation steps: Ensure the synthetic data generator is trained on high-quality, diverse real data. Statistically compare distributions. Crucially, validate that models trained on synthetic+real data perform as well or better on held-out real data. Assess for privacy leakage.

Build a case with evidence: A) Show that a score alone doesn't change clinician behavior (cite literature). B) Propose a prototype where the score is linked to an actionable 'Prevention Plan' order set. C) Argue that ROI comes from completed interventions, not just scores.

Must address digital divide. Propose: 1) Develop a simplified version using only EHR data for non-wearable users. 2) Design the wearable interface with extreme simplicity and accessibility. 3) Provide community health worker support for onboarding. 4) Monitor model performance across demographics.

This corrupts the input data and model trust. Adaptations: 1) Build anomaly detection algorithms for gaming. 2) Shift focus to outcomes that can't be gamed (e.g., lab results). 3) Redesign the incentive system from 'score' to 'engagement with verified healthy activities.'

Frame in terms of long-term value, not short-term cost. Use health economics: Model the predicted reduction in late-stage treatment costs (e.g., cancer chemotherapy) versus the cost of early screening. Present a cost-effectiveness analysis (e.g., cost per QALY gained).

The model learns obsolete patterns, leading to harmful recommendations. Remediation: 1) Immediately audit model recommendations against current guidelines. 2) Curate a new, temporally appropriate dataset. 3) Retrain and rigorously validate. 4) Implement a data 'staleness' monitoring alert.

Pipeline: Data (FHIR API -> ETL on Airflow/Spark) -> Feature Store (Feast/Tecton) -> Model Training (SageMaker/Vertex) -> Validation (Great Expectations for data, custom fairness tests) -> Deployment (Kubernetes/TFServing) -> Monitoring (Prometheus for infra, Evidently AI for data/model drift).

Workflow: 1) Ingest and chunk medical guidelines (PDFs, HTML). 2) Create embeddings (e.g., OpenAI Ada) and store in a vector DB (Pinecone, Weaviate). 3) Build a chain that retrieves relevant guideline chunks based on a clinical query and generates a concise, cited answer using an LLM (GPT-4).

A feature store is a centralized repository for storing, managing, and serving ML features. In healthcare, it's valuable for: 1) Consistency (same 'HbA1c' feature definition for all models), 2) Reusability across projects, 3) Tracking feature lineage and staleness for compliance, and 4) Enabling low-latency serving for real-time risk prediction.

Types: 1) Data Drift (change in input distribution, e.g., new wearable sensor). 2) Concept Drift (change in relationship between input and output, e.g., new COVID strain). 3) Label Drift (change in outcome prevalence). Dangerous: Concept Drift. Monitor with statistical tests (KS-test) on feature and prediction distributions, and track model performance on a rolling cohort.

Use Federated Learning. Setup: Each hospital has a local training node. A central server coordinates the process. Steps: 1) Send global model to each hospital. 2) Each hospital trains on local data. 3) Only model updates (gradients), not data, are sent back and aggregated. Requires frameworks like TensorFlow Federated and careful handling of heterogeneous data.

Design a review queue. The model flags high-risk or uncertain predictions (e.g., confidence < threshold). These cases are routed to a clinician panel via a dashboard. The panel's decision (agree/disagree) is logged as feedback. This feedback is used to: 1) Override the model output for that patient, 2) Retrain the model periodically.

Lifecycle stages in the platform: 1) Experiment Tracking (SageMaker Experiments/Vertex ML Metadata) to log all runs. 2) Data Versioning (using S3/GCS with metadata). 3) Pipelines (SageMaker Pipelines/Vertex Pipelines) for automated, reproducible training. 4) Model Registry (SageMaker Model Registry/Vertex Model Registry) for versioning and approval gates. 5) Deployment with monitored endpoints. All steps generate audit trails.

Differential privacy adds controlled noise to data or model outputs to make it impossible to determine if any single individual was in the training set. Apply it by: 1) Using differentially private stochastic gradient descent (DP-SGD) during training, where noise is added to gradients. 2) Using libraries like TensorFlow Privacy or Opacus. Trade-off: Privacy guarantee vs. model utility (accuracy).

Look for: 1) Using a concrete analogy (e.g., a biased weighing scale). 2) Focusing on the business/clinical impact (e.g., 'This could lead to lawsuits and poorer outcomes for minority patients'). 3) Using visuals or stories. 4) Checking for understanding and inviting questions.

A good answer shows humility and user-centricity. The candidate should describe how they discovered the mis-framing (e.g., by talking to end-users, analyzing early results) and how they collaborated to reframe the problem around a true need, even if it meant starting over.

Should describe a systematic approach: curated RSS feeds/newsletters (e.g., The Batch, Stat News), key conferences (NeurIPS, AMIA), participation in specialized online communities (MLM, Health AI forums), and reading high-impact journals (Nature Medicine, JAMA).

Look for a structured approach: 1) Identifying the dilemma clearly (e.g., privacy vs. utility). 2) Consulting ethical frameworks and principles. 3) Seeking diverse perspectives (ethicists, clinicians, patient advocates). 4) Making a decision and documenting the rationale. 5) Being open to revisiting it.

Key strategies: 1) Starting with small, quick wins to demonstrate value. 2) Using their language and focusing on their pain points. 3) Involving them as co-designers from the start. 4) Being transparent about limitations and uncertainties. 5) Delivering on promises consistently.